Obesity Management in Primary Care During and Beyond the COVID-19 Pandemic

被引：2

作者：

Kameg, Brayden ^{[1
]}

Fradkin, Dina ^{[1
]}

机构：

[1] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA

来源：

JNP- THE JOURNAL FOR NURSE PRACTITIONERS | 2021年 / 17卷 / 04期

关键词：

COVID-19; lifestyle counseling; obesity; primary care; DEFICIT-HYPERACTIVITY DISORDER; ADULT ADHD; PREVALENCE; DIAGNOSIS; CHILDREN;

D O I：

10.1016/j.nurpra.2020.11.005

中图分类号：

R47 [护理学];

学科分类号：

1011 ;

摘要：

With 6.1 million United States cases as of early September 2020, the coronavirus disease 2019 (COVID-19) pandemic is presenting unprecedented challenges to primary care. As a complex multifactorial chronic disease, obesity is a significant risk for severe COVID-19 complications associated with high morbidity and mortality. Sustainable lifestyle changes and weight loss can be effective to address obesity and its complications. With COVID-19 expected to persist for the foreseeable future, treatment and prevention of obesity is more imperative than ever. This report summarizes how obesity management and lifestyle counseling can be incorporated and applied in primary care during and beyond the COVID-19 pandemic. (c) 2020 Elsevier Inc. All rights reserved.

引用

页码：432 / 436

页数：5

共 40 条

[1]

[Anonymous], 2013, DIAGN STAT MAN MENT

[2]

Barkley RA., 2020, ADHD REPORT, V28, P10, DOI [10.1521/adhd.2020.28.3.10, DOI 10.1521/ADHD.2020.28.3.10]

[3] The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials [J].

Catala-Lopez, Ferran ;

Hutton, Brian ;

Nunez-Beltran, Amparo ;

Page, Matthew J. ;

Ridao, Manuel ;

Macias St-Gerons, Diego ;

Catala, Miguel A. ;

Tabares-Seisdedos, Rafael ;

Moher, David .

PLOS ONE, 2017, 12 (07)

[4]

Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD), 2020, CLIN PRACT TOOLS

[5] Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD [J].

Clavenna, Antonio ;

Bonati, Maurizio .

EXPERT OPINION ON DRUG SAFETY, 2017, 16 (12) :1335-1345

[6] International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder [J].

Crunelle, Cleo L. ;

van den Brink, Wim ;

Moggi, Franz ;

Konstenius, Maija ;

Franck, Johan ;

Levin, Frances R. ;

van de Glind, Geurt ;

Demetrovics, Zsolt ;

Coetzee, Corne ;

Luderer, Mathias ;

Schellekens, Arnt ;

Matthys, Frieda .

EUROPEAN ADDICTION RESEARCH, 2018, 24 (01) :43-51

[7] Comorbidity between ADHD and anxiety disorders across the lifespan [J].

D'Agati, Elisa ;

Curatolo, Paolo ;

Mazzone, Luigi .

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2019, 23 (04) :238-244

[8] Prevalence of Parent-Reported ADHD Diagnosis and Associated Treatment Among US Children and Adolescents, 2016 [J].

Danielson, Melissa L. ;

Bitsko, Rebecca H. ;

Ghandour, Reem M. ;

Holbrook, Joseph R. ;

Kogan, Michael D. ;

Blumberg, Stephen J. .

JOURNAL OF CLINICAL CHILD AND ADOLESCENT PSYCHOLOGY, 2018, 47 (02) :199-212

[9]

De Crescenzo F, 2017, EVID-BASED MENT HEAL, V20, P4, DOI 10.1136/eb-2016-102415

[10] Comment on Prevalence and Correlates of Prescription Stimulant Use, Misuse, Use Disorders, and Motivations for Misuse Among Adults in the United States [J].

Diller, Lawrence .

AMERICAN JOURNAL OF PSYCHIATRY, 2019, 176 (01) :77-77

← 1 2 3 4 →